Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LLT-I1 is a sustained-release, drug-eluting contact lens being developed by MediPrint Ophthalmics for the treatment of post-cataract inflammation and pain. The product utilizes a proprietary 3D printing technology to incorporate the non-steroidal anti-inflammatory drug (NSAID) bromfenac into a hydrogel contact lens. This delivery system is designed to provide continuous, controlled release of the medication to the ocular surface, potentially improving therapeutic efficacy and patient compliance compared to conventional topical eye drops, which often suffer from poor adherence and rapid clearance. LLT-I1 is currently in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LLT-I1.